Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice

• Published in: Advances in experimental medicine and biology Vol. 1148; p. 279
• Main Authors: Bowden, S A, Foster, B L
• Format: Journal Article
• Language: English
• Published: United States 01-01-2019
• Subjects: Alkaline Phosphatase; Animals; Enzyme Replacement Therapy; Humans; Hypophosphatasia - therapy; Mice; Quality of Life; Alkaline phosphatase; Rickets; Teeth; Asfotase alfa; Bone mineralization; Osteomalacia; Hypophosphatasia
• ISSN: 0065-2598
• DOI: 10.1007/978-981-13-7709-9_13

Hypophosphatasia (HPP) is an inherited disorder that affects bone and tooth mineralization characterized by low serum alkaline phosphatase. HPP is caused by loss-of-function mutations in the ALPL gene encoding the protein, tissue-nonspecific alkaline phosphatase (TNSALP). TNSALP is expressed by mineralizing cells of the skeleton and dentition and is associated with the mineralization process. Generalized reduction of activity of the TNSALP leads to accumulation of its substrates, including inorganic pyrophosphate (PP
) that inhibits physiological mineralization. This leads to defective skeletal mineralization, with manifestations including rickets, osteomalacia, fractures, and bone pain, all of which can result in multi-systemic complications with significant morbidity, as well as mortality in severe cases. Dental manifestations are nearly universal among affected individuals and feature most prominently premature loss of deciduous teeth. Management of HPP has been limited to supportive care until the introduction of a TNSALP enzyme replacement therapy (ERT), asfotase alfa (AA). AA ERT has proven to be transformative, improving survival in severely affected infants and increasing overall quality of life in children and adults with HPP. This chapter provides an overview of TNSALP expression and functions, summarizes HPP clinical types and pathologies, discusses early attempts at therapies for HPP, summarizes development of HPP mouse models, reviews design and validation of AA ERT, and provides up-to-date accounts of AA ERT efficacy in clinical trials and case reports, including therapeutic response, adverse effects, limitations, and potential future directions in therapy.